Novel delta subunit mutation in slow-channel syndrome causes severe weakness by novel mechanisms

Christopher M. Gomez, Ricardo A Maselli, Bhupinder P S Vohra, Manuel F Navedo, Joel R. Stiles, Pierre Charnet, Kelly Schott, Legier Rojas, John Keesey, Anthony Verity, Robert W. Wollmann, Jose Lasalde-Dominicci

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

We investigated the basis for a novel form of the slow-channel congenital myasthenic syndrome presenting in infancy in a single individual as progressive weakness and impaired neuromuscular transmission without overt degeneration of the motor endplate. Prolonged low-amplitude synaptic currents in biopsied anconeus muscle at 9 years of age suggested a kinetic disorder of the muscle acetylcholine receptor. Ultrastructural studies at 16 months, at 9 years, and at 15 years of age showed none of the typical degenerative changes of the endplate associated with the slow-channel congenital myasthenic syndrome, and acetylcholine receptor numbers were not significantly reduced. We identified a novel C-to-T substitution in exon 8 of the δ-subunit that results in a serine to phenylalanine mutation in the region encoding the second transmembrane domain that lines the ion channel. Using Xenopus oocyte in vitro expression studies we confirmed that the δS268F mutation, as with other slow-channel congenital myasthenic syndrome mutations, causes delayed closure of acetylcholine receptor ion channels. In addition, unlike other mutations in slow-channel congenital myasthenic syndrome, this mutation also causes delayed opening of the channel, a finding that readily explains the marked congenital weakness in the absence of endplate degeneration. Finally, we used serial morphometric analysis of electron micrographs to explore the basis for the progressive weakness and decline of amplitude of endplate currents over a period of 14 years. We demonstrated a progressive widening and accumulation of debris in the synaptic cleft, resulting in loss of efficacy of released neurotransmitter and reduced safety factor. These studies demonstrate the role of previously unrecognized mechanisms of impairment of synaptic transmission caused by a novel mutation and show the importance of serial in vitro studies to elucidate novel disease mechanisms.

Original languageEnglish (US)
Pages (from-to)102-112
Number of pages11
JournalAnnals of Neurology
Volume51
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Congenital Myasthenic Syndromes
Mutation
Cholinergic Receptors
Ion Channels
Motor Endplate
Muscular Diseases
Xenopus
Phenylalanine
Synaptic Transmission
Serine
Oocytes
Neurotransmitter Agents
Exons
Electrons
Safety
Muscles

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Novel delta subunit mutation in slow-channel syndrome causes severe weakness by novel mechanisms. / Gomez, Christopher M.; Maselli, Ricardo A; Vohra, Bhupinder P S; Navedo, Manuel F; Stiles, Joel R.; Charnet, Pierre; Schott, Kelly; Rojas, Legier; Keesey, John; Verity, Anthony; Wollmann, Robert W.; Lasalde-Dominicci, Jose.

In: Annals of Neurology, Vol. 51, No. 1, 2002, p. 102-112.

Research output: Contribution to journalArticle

Gomez, CM, Maselli, RA, Vohra, BPS, Navedo, MF, Stiles, JR, Charnet, P, Schott, K, Rojas, L, Keesey, J, Verity, A, Wollmann, RW & Lasalde-Dominicci, J 2002, 'Novel delta subunit mutation in slow-channel syndrome causes severe weakness by novel mechanisms', Annals of Neurology, vol. 51, no. 1, pp. 102-112. https://doi.org/10.1002/ana.10077
Gomez, Christopher M. ; Maselli, Ricardo A ; Vohra, Bhupinder P S ; Navedo, Manuel F ; Stiles, Joel R. ; Charnet, Pierre ; Schott, Kelly ; Rojas, Legier ; Keesey, John ; Verity, Anthony ; Wollmann, Robert W. ; Lasalde-Dominicci, Jose. / Novel delta subunit mutation in slow-channel syndrome causes severe weakness by novel mechanisms. In: Annals of Neurology. 2002 ; Vol. 51, No. 1. pp. 102-112.
@article{09411a7b68804b33918d7726188706c0,
title = "Novel delta subunit mutation in slow-channel syndrome causes severe weakness by novel mechanisms",
abstract = "We investigated the basis for a novel form of the slow-channel congenital myasthenic syndrome presenting in infancy in a single individual as progressive weakness and impaired neuromuscular transmission without overt degeneration of the motor endplate. Prolonged low-amplitude synaptic currents in biopsied anconeus muscle at 9 years of age suggested a kinetic disorder of the muscle acetylcholine receptor. Ultrastructural studies at 16 months, at 9 years, and at 15 years of age showed none of the typical degenerative changes of the endplate associated with the slow-channel congenital myasthenic syndrome, and acetylcholine receptor numbers were not significantly reduced. We identified a novel C-to-T substitution in exon 8 of the δ-subunit that results in a serine to phenylalanine mutation in the region encoding the second transmembrane domain that lines the ion channel. Using Xenopus oocyte in vitro expression studies we confirmed that the δS268F mutation, as with other slow-channel congenital myasthenic syndrome mutations, causes delayed closure of acetylcholine receptor ion channels. In addition, unlike other mutations in slow-channel congenital myasthenic syndrome, this mutation also causes delayed opening of the channel, a finding that readily explains the marked congenital weakness in the absence of endplate degeneration. Finally, we used serial morphometric analysis of electron micrographs to explore the basis for the progressive weakness and decline of amplitude of endplate currents over a period of 14 years. We demonstrated a progressive widening and accumulation of debris in the synaptic cleft, resulting in loss of efficacy of released neurotransmitter and reduced safety factor. These studies demonstrate the role of previously unrecognized mechanisms of impairment of synaptic transmission caused by a novel mutation and show the importance of serial in vitro studies to elucidate novel disease mechanisms.",
author = "Gomez, {Christopher M.} and Maselli, {Ricardo A} and Vohra, {Bhupinder P S} and Navedo, {Manuel F} and Stiles, {Joel R.} and Pierre Charnet and Kelly Schott and Legier Rojas and John Keesey and Anthony Verity and Wollmann, {Robert W.} and Jose Lasalde-Dominicci",
year = "2002",
doi = "10.1002/ana.10077",
language = "English (US)",
volume = "51",
pages = "102--112",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Novel delta subunit mutation in slow-channel syndrome causes severe weakness by novel mechanisms

AU - Gomez, Christopher M.

AU - Maselli, Ricardo A

AU - Vohra, Bhupinder P S

AU - Navedo, Manuel F

AU - Stiles, Joel R.

AU - Charnet, Pierre

AU - Schott, Kelly

AU - Rojas, Legier

AU - Keesey, John

AU - Verity, Anthony

AU - Wollmann, Robert W.

AU - Lasalde-Dominicci, Jose

PY - 2002

Y1 - 2002

N2 - We investigated the basis for a novel form of the slow-channel congenital myasthenic syndrome presenting in infancy in a single individual as progressive weakness and impaired neuromuscular transmission without overt degeneration of the motor endplate. Prolonged low-amplitude synaptic currents in biopsied anconeus muscle at 9 years of age suggested a kinetic disorder of the muscle acetylcholine receptor. Ultrastructural studies at 16 months, at 9 years, and at 15 years of age showed none of the typical degenerative changes of the endplate associated with the slow-channel congenital myasthenic syndrome, and acetylcholine receptor numbers were not significantly reduced. We identified a novel C-to-T substitution in exon 8 of the δ-subunit that results in a serine to phenylalanine mutation in the region encoding the second transmembrane domain that lines the ion channel. Using Xenopus oocyte in vitro expression studies we confirmed that the δS268F mutation, as with other slow-channel congenital myasthenic syndrome mutations, causes delayed closure of acetylcholine receptor ion channels. In addition, unlike other mutations in slow-channel congenital myasthenic syndrome, this mutation also causes delayed opening of the channel, a finding that readily explains the marked congenital weakness in the absence of endplate degeneration. Finally, we used serial morphometric analysis of electron micrographs to explore the basis for the progressive weakness and decline of amplitude of endplate currents over a period of 14 years. We demonstrated a progressive widening and accumulation of debris in the synaptic cleft, resulting in loss of efficacy of released neurotransmitter and reduced safety factor. These studies demonstrate the role of previously unrecognized mechanisms of impairment of synaptic transmission caused by a novel mutation and show the importance of serial in vitro studies to elucidate novel disease mechanisms.

AB - We investigated the basis for a novel form of the slow-channel congenital myasthenic syndrome presenting in infancy in a single individual as progressive weakness and impaired neuromuscular transmission without overt degeneration of the motor endplate. Prolonged low-amplitude synaptic currents in biopsied anconeus muscle at 9 years of age suggested a kinetic disorder of the muscle acetylcholine receptor. Ultrastructural studies at 16 months, at 9 years, and at 15 years of age showed none of the typical degenerative changes of the endplate associated with the slow-channel congenital myasthenic syndrome, and acetylcholine receptor numbers were not significantly reduced. We identified a novel C-to-T substitution in exon 8 of the δ-subunit that results in a serine to phenylalanine mutation in the region encoding the second transmembrane domain that lines the ion channel. Using Xenopus oocyte in vitro expression studies we confirmed that the δS268F mutation, as with other slow-channel congenital myasthenic syndrome mutations, causes delayed closure of acetylcholine receptor ion channels. In addition, unlike other mutations in slow-channel congenital myasthenic syndrome, this mutation also causes delayed opening of the channel, a finding that readily explains the marked congenital weakness in the absence of endplate degeneration. Finally, we used serial morphometric analysis of electron micrographs to explore the basis for the progressive weakness and decline of amplitude of endplate currents over a period of 14 years. We demonstrated a progressive widening and accumulation of debris in the synaptic cleft, resulting in loss of efficacy of released neurotransmitter and reduced safety factor. These studies demonstrate the role of previously unrecognized mechanisms of impairment of synaptic transmission caused by a novel mutation and show the importance of serial in vitro studies to elucidate novel disease mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=0036135172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036135172&partnerID=8YFLogxK

U2 - 10.1002/ana.10077

DO - 10.1002/ana.10077

M3 - Article

C2 - 11782989

AN - SCOPUS:0036135172

VL - 51

SP - 102

EP - 112

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 1

ER -